Scaling GLP-1 Obesity Trials Without Losing DXA Data

The explosive growth of global obesity trials, fueled by the success of GLP-1 receptor agonist therapies, presents a critical challenge: ensuring complete and scientifically sound data capture, particularly from dual-energy X-ray absorptiometry (DXA) scans. ICON, a leading clinical research organization, has pioneered a pragmatic and scalable DXA strategy that addresses the logistical limitations of imaging larger body types, thereby preserving crucial visceral fat datasets and preventing the detrimental phenomenon of "silent attrition" from incomplete imaging. This innovative approach is vital for maintaining the integrity of these high-stakes clinical studies and accelerating the delivery of potentially life-changing treatments to patients worldwide.

The landscape of obesity treatment is undergoing a profound transformation, driven by the remarkable efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists. Medications such as semaglutide (marketed as Ozempic, Wegovy, and Rybelsus) and tirzepatide (marketed as Mounjaro and Zepbound) have demonstrated unprecedented success in facilitating significant weight loss, prompting a surge in pharmaceutical investment and clinical trial activity. This escalating interest has led to the launch of expansive global studies, often involving thousands of participants across hundreds of research sites. These trials are not only vying for a finite pool of eligible patients but are also under immense pressure to recruit rapidly, retain participants effectively, and maximize the quality and completeness of the data collected to support regulatory submissions and demonstrate the long-term benefits of these therapies.

Context: The GLP-1 Scale Raises the Stakes for Complete Datasets

The advent of GLP-1 therapies has irrevocably altered the trajectory of obesity research. Leading pharmaceutical companies, including Novo Nordisk and Eli Lilly, have invested heavily in large-scale clinical programs to validate and expand the use of these drugs. For instance, Eli Lilly’s SURMOUNT-1 study, a pivotal trial for tirzepatide, successfully enrolled over 2,500 participants to unequivocally demonstrate the drug’s efficacy. Similarly, Novo Nordisk’s STEP 1 trial, investigating semaglutide, enrolled nearly 2,000 patients. Crucially, both of these landmark studies, and many others in the pipeline, incorporated whole-body DXA imaging substudies. These substudies are designed to provide detailed insights into body composition, specifically differentiating between fat mass, lean mass, and bone mineral density.

The intensity of competition within the obesity trial sector cannot be overstated. With multiple companies developing and testing similar therapeutic agents, the race to recruit participants and generate robust data is fierce. Sponsors face unprecedented pressure to optimize every aspect of their trial operations, from patient identification and screening to ongoing engagement and data collection. In this high-stakes environment, even seemingly minor logistical hurdles can have significant repercussions. When an estimated 10-15% of carefully recruited and engaged participants are at risk of being excluded from analyses due to incomplete imaging data, the impact on scientific integrity and trial timelines can be substantial. Imaging, therefore, transcends its role as a mere protocol requirement; it is evolving into a critical component of participant retention strategies, ensuring that every invested individual contributes to the study’s overall success.

The Utility and Limitations of DXA in Obesity Trials

Dual-energy X-ray absorptiometry (DXA) has become a cornerstone of obesity research due to its favorable attributes: speed, relative comfort for participants, and its ability to accurately differentiate between key body composition components. Its particular strength lies in its capacity to quantify visceral adipose tissue (VAT), the deep abdominal fat that surrounds internal organs and is a potent predictor of cardiometabolic risk, including cardiovascular disease and type 2 diabetes. Unlike more complex and time-consuming imaging modalities such as Magnetic Resonance Imaging (MRI), DXA offers a practical solution for large-scale studies.

However, a significant challenge has emerged with the increasing size of participants in obesity trials. Standard DXA machines are not inherently designed to accommodate individuals with larger body frames, particularly those with a higher waist circumference. Conventional DXA protocols typically involve positioning the participant centrally on the scanner table. For the majority of individuals, this positioning ensures that the entire torso and both limbs are within the scanner’s field of view. The data captured from one side of the body, including the torso, is often mirrored to estimate the composition of the contralateral side.

Maximising data capture in obesity trials - Pharmaceutical Technology

The critical issue arises for the approximately 10-15% of participants whose torsos are too large to fit entirely within the DXA scanner’s imaging plane when positioned according to standard protocols. In such cases, the scanner cannot capture a complete cross-section of the abdominal region. This results in incomplete visceral fat data, rendering it impossible to perform accurate and reliable visceral fat calculations. This limitation poses a dual threat: it compromises the scientific validity of the collected data and can inadvertently lead to participant exclusion from analyses. Participants who undergo the screening and imaging process, only to have their data deemed incomplete and unusable, are effectively lost to the study despite their initial commitment, contributing to "silent attrition." This loss not only diminishes the statistical power of the trial but also represents a wasted investment in patient recruitment and engagement.

ICON’s Innovative DXA Solution for 100% Data Capture

Recognizing the escalating risk of data loss directly attributable to the physical limitations of DXA equipment and standard protocols, ICON’s Medical Imaging and Cardiac Safety (IMC) team developed a sophisticated yet pragmatic solution. Their objective was to devise a scalable imaging strategy that could overcome these challenges and guarantee complete data capture for every participant, regardless of their body size. This strategy hinges on making subtle, yet impactful, modifications to established scan techniques, ensuring that the integrity of the scientific data remains paramount.

ICON implemented a two-pronged approach, carefully tailoring DXA scan protocols to accommodate a wider range of body types:

Modified Hand Positioning: Instead of the standard protocol where hands are placed above the head, participants are instructed to place their arms by their sides. This seemingly minor adjustment has a significant impact. By allowing the arms to rest alongside the torso, the overall lateral dimension of the participant is reduced, increasing the likelihood that the entire torso, including the abdominal region, will fit within the scanner’s field of view. This modification is crucial for obtaining a complete axial scan of the abdomen, which is essential for accurate visceral fat quantification.
Dual-Scan Workflow with Centralized Review: For participants whose torsos still present a challenge even with the modified hand positioning, ICON employs a dual-scan workflow. In this scenario, the participant undergoes two separate scans of the abdominal region. The first scan captures the area from the diaphragm down to the iliac crest. The second scan then focuses on the remaining lower abdominal area. These two partial scans are subsequently merged by highly trained specialists during a centralized review process. This meticulous merging ensures that a complete and contiguous image of the entire abdominal cavity is reconstructed, allowing for comprehensive visceral fat analysis.

To ensure the consistent and accurate application of these modified protocols across a global network of research sites – in this specific instance, numbering around 100 – ICON’s IMC team provided comprehensive support. This included the development of detailed imaging manuals that clearly outlined the revised procedures, along with rigorous training modules for all imaging technicians involved. The commitment to quality extended to the post-scan analysis phase. All acquired imaging data was centralized and subjected to expert review by a dedicated team of specialists. These professionals were responsible for analyzing, validating, and ultimately merging the dual scans where necessary, thereby preserving both the accuracy of the measurements and the operational efficiency of the trial. This centralized oversight model is instrumental in minimizing inter-site variability and ensuring the highest standards of data quality across a geographically dispersed study.

Future-Proofing Obesity Imaging: Beyond Weight Loss

The evolving nature of obesity research underscores the increasing importance of sophisticated imaging techniques. As the scientific community moves beyond simply measuring weight loss, there is a growing emphasis on understanding the quality of that weight loss. This involves differentiating between the reduction of fat mass versus lean mass, and crucially, distinguishing between subcutaneous fat (located just beneath the skin) and visceral fat (deep within the abdominal cavity). This nuanced understanding is critical for assessing the long-term health impacts and metabolic benefits of GLP-1 therapies.

While MRI offers superior resolution and capabilities for discerning fat and muscle tissue with greater precision – allowing for the exclusion of organs and major blood vessels from muscle tissue measurements – it remains a more resource-intensive modality. MRI is often reserved for smaller patient subgroups or early-phase studies due to its higher cost and logistical complexity.

DXA, on the other hand, continues to be the most feasible and cost-effective imaging modality for large-scale, multi-center obesity trials. Its ability to provide rapid and efficient scans that quantify the torso, limbs, and head, while also separating visceral from subcutaneous fat within the abdomen, makes it indispensable. The identification and quantification of visceral fat are particularly important, given its strong and well-established association with major adverse cardiovascular events (MACE). Innovations like ICON’s pragmatic DXA strategy enable these critical distinctions to be made, supporting a deeper understanding of how these therapies influence overall metabolic health and reduce cardiovascular risk.

ICON’s approach directly addresses the need for high-quality imaging in diverse patient populations. By ensuring that DXA can be effectively implemented even in individuals with larger body types, the strategy actively combats the problem of "silent attrition." This proactive imaging design complements the multi-level, multi-channel recruitment and patient engagement strategies that are already in place within obesity trials to mitigate high dropout rates. Ultimately, by safeguarding data integrity and improving participant retention, these imaging innovations directly support the timely completion of clinical trials and the generation of meaningful, reliable outcomes.

Outcome: Complete Data, Full Value

The implementation of ICON’s scalable DXA scan technique offers a tangible and significant benefit to sponsors of global obesity trials. By enabling complete visceral fat analysis for every participant, this strategy effectively mitigates data loss from an estimated 10-15% of study cohorts who might otherwise yield incomplete scans. This not only preserves the scientific integrity of the trials, ensuring that conclusions drawn are based on comprehensive data, but also safeguards operational timelines and budgets. The avoidance of incomplete datasets prevents costly delays associated with data remediation, re-scans, or the need to recruit additional participants to compensate for lost data.

In the fiercely competitive landscape of obesity research, where patient recruitment is a hard-won battle and participant retention is paramount to success, a proactive and robust imaging design represents a distinct strategic advantage. ICON’s innovative approach demonstrates a commitment to anticipating and overcoming logistical challenges inherent in large-scale clinical trials. By ensuring that crucial body composition data, such as visceral fat levels, is captured accurately and completely, sponsors can gain a more profound understanding of the efficacy and safety profiles of their investigational therapies. This leads to more robust evidence packages for regulatory review and ultimately, accelerates the availability of effective obesity treatments to the millions of individuals who stand to benefit.

ICON’s Medical Imaging team is at the forefront of developing and implementing such essential strategies. Their expertise in medical imaging solutions is designed to maximize data capture and ensure the highest levels of data integrity and participant retention, thereby driving meaningful outcomes in critical therapeutic areas like obesity.

RELATED CONTENT: